Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report

Summary Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) generally has a favorable prognosis when compared to lung cancer without this alteration due to the advent of EGFR tyrosine kinase inhibitors (TKI). However, during treatment with these drugs, acquired resista...

Full description

Saved in:
Bibliographic Details
Published inMemo - Magazine of European medical oncology Vol. 17; no. 2; pp. 107 - 109
Main Authors Müser, Nino Rafael, Kirchbacher, Klaus, Funk, Georg-Christian
Format Journal Article
LanguageEnglish
Published Vienna Springer Vienna 01.05.2024
Subjects
Case Report
Medicine
Medicine & Public Health
Oncology
Afatinib
Tyrosine kinase inhibitor
Rebiopsy
Immunotherapy
Resistance mechanism
Online AccessGet full text

Cover

More Information
Summary:Summary Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) generally has a favorable prognosis when compared to lung cancer without this alteration due to the advent of EGFR tyrosine kinase inhibitors (TKI). However, during treatment with these drugs, acquired resistance and in turn progressive disease eventually occur. One such resistance mechanism is the transformation of EGFR-mutant adenocarcinoma into small cell lung cancer (SCLC) which has been described in a small subset of patients. We report the case of a woman with stage IV adenocarcinoma progressing and transforming into SCLC while being treated with Afatinib at our institution. This case also highlights the importance of rebiopsy in progressive patients receiving TKI for EGFR-mutated NSCLC.
ISSN:1865-5041
1865-5076
DOI:10.1007/s12254-023-00953-7